United Therapeutics Chairperson & CEO Executes Rule 10b5-1 Option Exercise and Sale

Insider Transaction Overview

On October 12, 2026, Dr. Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (NASDAQ: UTHR), executed transactions consisting of the exercise of stock options and the complete sale of the acquired shares under a pre-arranged Rule 10b5-1 trading plan.

Key Details:

• Derivative Exercise: Exercised 9,500 options expiring March 15, 2027, at an exercise price of $117.76 per share (total cost: $1,118,720).
• Open Market Sales: Sold all 9,500 shares through multiple tranches at weighted average prices ranging from $548.13 to $554.46 per share, generating aggregate proceeds of approximately $5,231,666.
• Net Cash Realized (Pre-Tax): Approximately $4,112,946.
• Trading Plan: Executed pursuant to a Rule 10b5-1 trading plan established on November 7, 2025.

Post-Transaction Holdings:

• Following these transactions, the trust holds 324,443 shares directly associated with this reporting line.
• Dr. Rothblatt continues to maintain substantial direct and indirect holdings, including 40,513 direct common shares, multiple trust holdings totaling over 300,000 additional shares, and 252,410 stock options remaining in the trust.

Market Impact & Interpretation:

Because this activity reflects an automated, scheduled exercise-and-sale under a 10b5-1 plan adopted nearly a year prior, it represents standard executive equity monetization rather than an ad-hoc discretionary trade based on near-term corporate developments.